Back to Search
Start Over
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.
- Source :
-
BMC pulmonary medicine [BMC Pulm Med] 2019 Nov 11; Vol. 19 (1), pp. 209. Date of Electronic Publication: 2019 Nov 11. - Publication Year :
- 2019
-
Abstract
- Background: Lung cancer is one of the most incident neoplastic diseases, and a leading cause of death for cancer worldwide. Knowledge of the incidence of druggable genetic alterations, their correlation with clinical and pathological features of the disease, and their interplay in cases of co-occurrence is crucial for selecting the best therapeutic strategies of patients with non-small cell lung cancer. In this real-life study, we describe the molecular epidemiology of genetic alterations in five driver genes and their correlations with the demographic and clinical characteristics of Sardinian patients with lung adenocarcinoma.<br />Methods: Data from 1440 consecutive Sardinian patients with a histologically proven diagnosis of lung adenocarcinoma from January 2011 through July 2016 were prospectively investigated. EGFR mutation analysis was performed for all of them, while KRAS and BRAF mutations were searched in 1047 cases; ALK alterations were determined with fluorescence in situ hybridization in 899 cases, and cMET amplifications in 788 cases.<br />Results: KRAS mutations were the most common genetic alterations involving 22.1% of the cases and being mutually exclusive with the EGFR mutations, which were found in 12.6% of them. BRAF mutations, ALK rearrangements, and cMET amplifications were detected in 3.2, 5.3, and 2.1% of the cases, respectively. Concomitant mutations were detected only in a few cases.<br />Conclusions: Almost all the genetic alterations studied showed a similar incidence in comparison with other Caucasian populations. Concomitant mutations were rare, and they probably have a scarce impact on the clinical management of Sardinians with lung adenocarcinoma. The low incidence of concomitant cMET amplifications at diagnosis suggests that these alterations are acquired in subsequent phases of the disease, often during treatment with TKIs.
- Subjects :
- Adenocarcinoma of Lung epidemiology
Adenocarcinoma of Lung metabolism
Adult
Aged
Aged, 80 and over
Anaplastic Lymphoma Kinase metabolism
Biomarkers, Tumor genetics
Biomarkers, Tumor metabolism
DNA Mutational Analysis
DNA, Neoplasm genetics
ErbB Receptors genetics
ErbB Receptors metabolism
Female
Humans
In Situ Hybridization, Fluorescence
Incidence
Italy epidemiology
Lung Neoplasms epidemiology
Lung Neoplasms metabolism
Male
Middle Aged
Prospective Studies
Proto-Oncogene Proteins c-met metabolism
Proto-Oncogene Proteins p21(ras) metabolism
Survival Rate trends
Adenocarcinoma of Lung genetics
Anaplastic Lymphoma Kinase genetics
Lung Neoplasms genetics
Mutation
Proto-Oncogene Proteins c-met genetics
Proto-Oncogene Proteins p21(ras) genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1471-2466
- Volume :
- 19
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- BMC pulmonary medicine
- Publication Type :
- Academic Journal
- Accession number :
- 31711449
- Full Text :
- https://doi.org/10.1186/s12890-019-0964-x